Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Person writing with pen

Association between a selective 5-HT4 receptor agonist and incidence of major depressive disorder: emulated target trial.

de Cates AN. et al, (2024), Br J Psychiatry, 1 - 8

The recombinant shingles vaccine is associated with lower risk of dementia.

Taquet M. et al, (2024), Nat Med

Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.

Taquet M. et al, (2024), Brain Commun, 6

GRIN2A (NR2A): a gene contributing to glutamatergic involvement in schizophrenia.

Harrison PJ. and Bannerman DM., (2023), Mol Psychiatry

Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization.

Taquet M. et al, (2023), Nat Med

Sex and age effects on risk of non-traumatic subarachnoid hemorrhage: Retrospective cohort study of 124,234 cases using electronic health records

Harrison CH. et al, (2023), Journal of Stroke and Cerebrovascular Diseases, 32, 107196 - 107196

Bipolar symptoms and lithium treatment affect neural signatures of adaptation of risk-taking to past outcomes during reward-guided decision-making

Scholl J. et al, (2023)

Glutamatergic dysfunction leads to a hyper-dopaminergic phenotype through deficits in short-term habituation: a mechanism for aberrant salience.

Panayi MC. et al, (2022), Mol Psychiatry

Little evidence supports gabapentinoid use in bipolar disorder or insomnia

Saul H. et al, (2022), BMJ (Clinical research ed.), 379

Incidence of Epilepsy and Seizures Over the First 6 Months After a COVID-19 Diagnosis: A Retrospective Cohort Study.

Taquet M. et al, (2022), Neurology

CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: Advances from functional genomics and pharmacoepidemiology.

Harrison PJ. et al, (2022), Neuropharmacology

Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.

Taquet M. et al, (2022), Lancet Psychiatry

New drug targets in psychiatry: Neurobiological considerations in the genomics era.

Harrison PJ. et al, (2022), Neurosci Biobehav Rev, 139

Response to the letter by Lin et al.

Taquet M. et al, (2022), Brain Behav Immun, 104

Impact of the COVID-19 Pandemic on the Global Delivery of Mental Health Services and Telemental Health: Systematic Review.

Zangani C. et al, (2022), JMIR Ment Health

Using a generative model of affect to characterize affective variability and its response to treatment in bipolar disorder.

Pulcu E. et al, (2022), Proc Natl Acad Sci U S A, 119

Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections.

Taquet M. et al, (2022), Brain Behav Immun, 103, 154 - 162

PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression.

Au-Yeung SK. et al, (2022), Evid Based Ment Health, 25, 77 - 83

Restricting the spread of SARS-CoV-2 or safeguarding mental health: a false dichotomy?

Taquet M. and Harrison PJ., (2022), Lancet Public Health, 7, e392 - e393

Catechol-O-methyltransferase activity does not influence emotional processing in men.

Martens MA. et al, (2022), J Psychopharmacol

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?